CEBPA and acute myeloid leukemia: Similar to the ELN 2010 risk stratification, low risk AML is defined as normal karyotype with NPM1 mutation and absence of FLT3 mutation, isolated biallelic CEBPA, or core binding factor AML [20, 21].